Altimmune presents promising data on pemvidutide's impact on cardioinflammatory lipids

From GlobeNewswire: 2024-06-22 16:45:00

Altimmune, Inc. presents data on pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH, at ADA’s 84th Scientific Sessions. Results show significant reduction in cardioinflammatory lipids without weight loss correlation. Pemvidutide decreases total cholesterol, LDL-C, and triglycerides by 28%, 26%, and 38% respectively, impacting CVD risk factors. GlycA and GlycB biomarkers of inflammation were also reduced. Systolic and diastolic blood pressure decreased with pemvidutide treatment, suggesting potential cardiovascular benefits. Pemvidutide’s pleiotropic effects and promising data support its development for obesity and MASH, holding FDA Fast Track designation. Learn more at www.altimmune.com.



Read more at GlobeNewswire: Altimmune Presents Data on the Effect of Pemvidutide on